NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Zapping growing tumors early may buy time for metastatic cancer patients
Disease control OngoingThis study looks at whether giving precise radiation to tumors that have just started to grow again can help people with metastatic breast or lung cancer live longer without their disease getting worse. About 107 adults with triple-negative breast cancer or certain types of lung …
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
Blood test may help track lung cancer drug effectiveness
Disease control OngoingThis study looks at whether a blood test (liquid biopsy) can help doctors see how well the drug brigatinib is working in people with a specific type of advanced lung cancer (ALK-positive NSCLC). About 33 patients will take brigatinib pills and give blood samples over time. The go…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated May 17, 2026 02:59 UTC
-
Blood test may steer lung cancer therapy in real time
Disease control OngoingThis study tests whether a simple blood test can tell if a lung cancer drug (pembrolizumab) is working early on. About 40 people with stage IV non-small cell lung cancer will have blood drawn at different times. If the test shows the drug isn't working well, patients may switch t…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Julia K. Rotow, MD • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for elderly lung cancer patients: targeted pill shows promise
Disease control OngoingThis study tests a daily pill called adagrasib in 68 patients with advanced lung cancer that has a specific KRAS mutation. It focuses on people aged 70 or older, or those with poor physical health, who have already tried other treatments. The goal is to see if the drug can shrink…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated May 04, 2026 16:22 UTC